XERS · Xeris Biopharma Holdings, Inc.
$10.11
+1.03 (+11.34%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$1.66B
Shares
182.32M
Volume · Oct 5
2.8M
Avg daily vol (3M)
2.17M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.08
Open$9.34
Day$9.04–9.34
52W close$5.29–9.98
Avg vol 30d2.6M
Short int8.1M · 4.4% float · 4.8d
Short vol49%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 4 wks
filed Aug 6, 2026
call held May 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$335.41M
Trailing 12 months
Net income (TTM)
−$17.16M
Trailing 12 months
Revenue growth YoY
+28.7%
Year over year
Operating margin
10.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.4%
Year over year · more shares
Price change (1Y)
+9.3%
Trailing year
Short interest
4.4%
Latest settlement · 4.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+26%
above
Price vs 50-day avg
+7%
above
RSI (14)
56
neutral
MACD trend
Positive
52-week position
81%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+52%
trailing
YTD return
+16%
this year
Relative strength
+40%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
1 of 241 funds reported for Sep 30 · net +99 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.42% of float · ▲ +0.2% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
241 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+143%
Y/Y
EPS growth
+100%
Y/Y
Free cash flow
$27.5M
Balance sheet
$109.3M
net debt
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Total revenue
· full-year 2026
Raised
$385M – $390M
Mar 31, 2026
$380M – $390M
changed to
Aug 6, 2026
$385M – $390M
prior FY $291.85M
midpoint +32.8% Y/Y
Guided vs delivered
· last 2 settled
Total net revenue
full year 2024
guided $190M – $200M
$203.07M
Beat +4.1%
Full-year 2023 revenue guidance
full year 2023
guided $160M – $165M
$163.91M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+26%
Bullish
Price vs 50-day avg
+7%
Bullish
RSI (14)
56
Neutral
MACD trend
Positive
Bullish
52-week position
81%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
1 of 241 funds reported for Sep 30 · net +99 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.42% of float · ▲ +0.2% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
241 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $9 · 81%
Range high $10
vs 200-day avg +26%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $34.4M | six months ended June 30, 2026 | — |
| Total Shares Outstanding | 182,320,306 | as of July 31, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XERS
this stock
Xeris Biopharma Holdings, Inc.
|
$1.66B | +15.7% | +142.7% | — | 4.4% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.7% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XERS | -0.2% | +5.7% | +52.1% | -5.0% | +15.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +0.0% | +6.2% | +39.9% | -5.9% | +2.8% |